AnaptysBio Inc Stock News

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F

SAN DIEGO, July 15, 2020 -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging.

Pandion Therapeutics has filed proposed terms for its IPO. The company is developing treatments for gastrointestinal and liver diseases.

Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8) * Akero Therapeutics Inc (NASDAQ: AKRO) * Altimmune I

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8) Akero Therapeutics Inc (...

Squarepoint Ops LLC cut its position in AnaptysBio Inc (NASDAQ:ANAB) by 15.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SE

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Legal & General Group Plc decreased its holdings in AnaptysBio Inc (NASDAQ:ANAB) by 50.6% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 6

Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of federal and state laws by certain officers of the companies listed below.

AnaptysBio (NASDAQ:ANAB) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Monday, Zacks.com reports. The firm currently has a $25.00 tar

AnaptysBio, Inc. (ANAB) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

AnaptysBio Inc (NASDAQ:ANAB) has received an average rating of “Hold” from the twelve research firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the

Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and succes

Is (ANAB) Outperforming Other Medical Stocks This Year?